Epigenetic profiling of Italian patients identified methylation sites associated with hereditary Transthyretin amyloidosis - De Lillo, Antonella; Pathak, Gita A.; De Angelis, Flavio; Di Girolamo, Marco; Luigetti, Marco; Sabatelli, Mario; Perfetto, Federico; Frusconi, Sabrina; Manfellotto, Dario; Fuciarelli, Maria; Polimanti, Renato (medRxiv, 2020)
Hereditary Transthyretin (TTR) Amyloidosis (hATTR) is a rare life-threatening disorder caused by amyloidogenic coding mutations located in TTR gene. To understand the high phenotypic variability observed among carriers of TTR disease-causing mutations, we conducted an epigenome-wide association study (EWAS) assessing more than 700,000 methylation sites and testing epigenetic difference of TTR coding mutation carriers vs. non-carriers, We observed a significant methylation change at cg09097335 site located in Beta-secretase 2 (BACE2) gene (beta =-0.60, p=6.26×10−8). This gene is involved in a protein interaction network enriched for biological processes and molecular pathways related to amyloid-beta metabolism (Gene Ontology:0050435, q=0.007), amyloid fiber formation (Reactome HSA-977225, q=0.008), and Alzheimer’s disease (KEGG hsa05010, q=2.2×10−4). Additionally, TTR and BACE2 share APP (Amyloid-beta precursor protein) as a validated protein interactor. Within TTR gene region, we observed that Val30Met disrupts a methylation site, cg13139646, causing a drastic hypomethylation in carriers of this amyloidogenic mutation (beta=-2.18, p=3.34×10−11). Cg13139646 showed co-methylation with cg19203115 (r2=0.32), which showed significant epigenetic differences between symptomatic and asymptomatic carriers of amyloidogenic mutations (beta=-0.56, p=8.6×10−4). In conclusion, we provide novel insights related to the molecular mechanisms involved in the complex heterogeneity of hATTR, highlighting the role of epigenetic regulation in this rare disorder.Competing Interest StatementDrs. Fuciarelli and Polimanti received research grants from Pfizer Inc. to conduct epigenetic studies of hATTR. The other authors reported no biomedical financial interests or potential conflicts of interest.Funding StatementThis study was supported by an Investigator-Initiated Research from Pfizer Inc. to the University of Rome Tor Vergata. Pfizer Inc. had no role in the study design, data analysis, and results interpretation of the present study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the findings of this study are available within this article and its additional files.ADAlzheimer diseaseAPPamyloid beta precursor proteinhATTRHereditary transthyretin amyloidosisBACE1beta-secretase 1B4GALT6beta-1,4-Galactosyltransferase 6BACE2beta-secretase 2DSC2descmocollin-2DSC3desmocollin-3DSG3desmoglein-3EWASepigenome-wide association studiesFDRfalse discovery rateFYNFYN proto-oncogene, Src family tyrosine kinaseIGHV3-11immunoglobulin heavy variable 3-11TTRtransthyretin